oru.sePublikationer
Ändra sökning
Avgränsa sökresultatet
1 - 7 av 7
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Träffar per sida
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
Markera
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 1.
    Evans, M.
    et al.
    University Hospital Llandough, Cardiff, UK.
    Ridderstråle, M.
    Steno Diabetes Center, Gentofte, Denmark.
    Jensen, H. H.
    Incentive, Holte, Denmark.
    Bøgelund, M.
    Novo Nordisk Ltd., Gatwick, United Arab Emirates.
    Jensen, M. M.
    Novo Nordisk, Copenhagen, Denmark.
    Ericsson, Å.
    Novo Nordisk Scandinavia AB, Malmö, Sweden.
    Jendle, Johan
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Quantifying The Short-Term Impact of Changes In Hba1c, Weight And Insulin Regimen on Health Related Quality-of-Life2015Ingår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 7, s. A616-A616Artikel i tidskrift (Refereegranskat)
  • 2.
    Jendle, Johan
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Birkenfeld, A. L.
    Technical University Dresden, Dresden, Germany.
    Silver, R.
    Southern New Hampshire Diabetes and Endocrinology, Nashua NH, USA.
    Uusinarkaus, K.
    CSHP / DaVita Clinical Research, Colorado Springs CO, USA.
    Højbjerre, L.
    Novo Nordisk A/S, Søborg, Denmark.
    Thomsen, H. F.
    Novo Nordisk A/S, Søborg, Denmark.
    Davies, M.
    Diabetes Research Centre, University of Leicester, Leicester, UK.
    Effect of Gastrointestinal Adverse Events on Treatment Satisfaction in Semaglutide Treatment of Type 2 Diabetes2017Ingår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A484-A484Artikel i tidskrift (Övrigt vetenskapligt)
  • 3.
    Jendle, Johan
    et al.
    Örebro universitet, Institutionen för hälsovetenskap och medicin.
    Ridderstrale, M.
    Steno Diabetes, Gentofte, Denmark.
    Jensen, H. H.
    Incentive, Holte, Denmark.
    Bøgelund, M.
    Incentive, Holte, Denmark..
    Jensen, M. M.
    Novo Nordisk, Copenhagen, Denmark.
    Ericsson, A.
    Novo Nordisk Scandinavia AB, Malmö, Sweden.
    Evans, M.
    University Hospital Llandough, Cardiff, UK.
    Investigating the short-term impact of poor glycemic control on the daily lives of people with type 2 diabetes2015Ingår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 3, s. A65-A65Artikel i tidskrift (Övrigt vetenskapligt)
  • 4. Jensen, A. , V
    et al.
    Fraenkel, C. J.
    Skåne Univ Hosp, Lund, Sweden.
    Akesson, P.
    Skåne Univ Hosp, Lund, Sweden.
    Norén, Torbjörn
    Region Örebro län.
    Rundlof Nygren, P.
    Uppsala Univ Hosp, Uppsala, Sweden.
    Lennebratt, D.
    Uppsala Univ Hosp, Uppsala, Sweden.
    Hagberg, L.
    Sahigrenska Univ Hosp, Gothenburg, Sweden.
    The Cost Of Treating Recurrent Clostridium Difficile Infection In Patients Attending Infectious Disease Clinics At Four Hospitals In Sweden2015Ingår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 7, s. A583-A583Artikel i tidskrift (Refereegranskat)
  • 5.
    Klinkenbijl, B.
    et al.
    Dexcom Inc, Essertines Sur Rolle, Switzerland.
    Jendle, Johan
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Chaugule, S.
    Dexcom Inc, San Diego CA, USA.
    Graham, C.
    Dexcom Inc, San Diego CA, USA.
    Evaluation Of The Long-Term Cost-Effectiveness Of Real Time Continuous Glucose Monitoring (Rtcgm) Versus Self Monitoring Of Blood Glucose (Smbg) Alone In Type 1 Diabetes From The Swedish Societal Perspective2017Ingår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A585-A585Artikel i tidskrift (Övrigt vetenskapligt)
    Abstract [en]

    Objectives: To evaluate the cost-effectiveness of Real-Time CGM (RTCGM (G5)) compared to SMBG alone in Type 1 Diabetes (T1DM) patients using Multiple Daily Injections (MDI) from the Swedish societal perspective.

    Methods: The Quintiles IMS CORE Diabetes Model (CDM) (v. 9.0) was used to assess the long-term (50 year) cost-effectiveness of RTCGM compared to SMBG alone for a T1DM cohort. Treatment effects and base-line characteristics of patients were sourced from the recently published DIAMOND trial while all other assumptions and costs were sourced from earlier publications. The accuracy and clinical effectiveness of RTCGM (G5) is equivalent to that seen in CGM (G4SW505) used in the DIAMOND trial. Base case (BC) assumptions included a) starting HbA1c 8.6%; b) change in HbA1c: -1.0% for CGM group, -0.4% for SMBG alone; c) 50% reduction in severe hypoglycemic events (SHEs) and 33% reduction in non-severe hypoglycemic events (NSHEs) for the CGM group; d) dis-utilities of -0.0142 for NSHEs and SHEs not requiring medical interven-tion, and -0.047 for SHEs requiring medical resources. Treatment costs and outcomes were discounted at 3%.

    Results: The Incremental Cost-Effectiveness Ratio (ICER) for RTCGM vs. SMBG was SEK 180,530/QALY in the base-case. Sensitivity analyses showed the results were sensitive to changes in percent reduction in severe hypoglycemic events and its associated dis-utilities. An ICER of SEK 188,697/QALY was the result of the sensitivity analysis using the treatment effects from the recent Swedish GOLD study using an earlier version RTCGM. The base-case results were mini-mally impacted by changing starting HbA1c levels and discount rates.

    Conclusions: RTCGM has the potential to improve clinical outcomes, quality of life and healthcare efficiencies for the large cohort of MDI-treated patients. The results of this evaluation show that RTCGM (G5) is cost effective within the MDI-treated T1DM population, assuming a willingness-to-pay threshold of SEK 500,000 per Quality-Adjusted Life Year in Sweden.

  • 6.
    Nilsson, F. O. L.
    et al.
    Dental and Pharmaceutical Benefits Agency, Stockholm, Sweden.
    Svensson, Mikael
    Örebro universitet, Handelshögskolan vid Örebro Universitet.
    Arnberg, K.
    Dental and Pharmaceutical Benefits Agency, Stockholm, Sweden.
    Reimbursement decisions for pharmaceuticals in Sweden: the impact of cost-effectiveness and disease severity2014Ingår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, nr 7, s. A327-A327Artikel i tidskrift (Övrigt vetenskapligt)
    Abstract [en]

    Objectives: The purpose of this study is to evaluate the impact of cost-effectiveness and disease severity on the drug reimbursement decisions made by the reimbursement agency TLV in Sweden.

    Methods: Cost-effectiveness is measured through the continuous variable cost per QALY, while disease severity is measured by a dichotomous variable indicating high- or not high disease severity. We analyze all reimbursement decisions from 2005 through 2011 where there is data available on cost per QALY and disease severity. Logistic regressions are used to evaluate the impact of cost-effectiveness and disease severity on the drug reimbursement decisions.

    Results: There are 102 decisions with the required data available, 86 where reimbursement was granted and 16 where reimbursement was denied. The median cost per QALY for the drugs that were granted reimbursement was 39 000 euro (9sek/euro), ranging from a negative cost per QALY (better and cheaper) to 136 000 euro. The median cost per QALY for the drugs that were denied reimbursement was 111 000 euro, ranging from 78 000 euro to 1 111 000 euro. The results from the logistic regression analysis show that both the cost per QALY and the level of disease severity are statistically significantly related to the probability of a drug being granted reimbursement. When the cost per QALY exceeds 56 000 euro for non-severe diseases, and 92 000 euro for severe diseases, the probability that reimbursement is denied is higher than the probability that reimbursement is granted.

    Conclusions: In Sweden, it is sometimes stated as a rule of thumb that 55 000 euro per QALY is a threshold for cost-effective interventions. Our model shows that at this cost-effectiveness ratio, the probability of a new drug becoming reimbursed is 91 % or 98 %, depending on disease severity

  • 7.
    Roze, S.
    et al.
    HEVA HEOR Sarl, Lyon, France.
    Gherardi, A.
    HEVA HEOR Sarl, Lyon, France.
    de Portu, S.
    Medtronic International Sàrl, Tolochenaz, Switzerland.
    Jendle, Johan
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Health-Economic Analysis Of The Use Of Sensor-Augmented Pump With Predictive Suspend Function (Sap) Therapy In Sweden Compared To Insulin Pump Therapy Alone (Csii), In Type 1 Diabetic Patients2016Ingår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 19, nr 7, s. A699-A699Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Objectives: To assess the cost-effectiveness and to project the clinical benefits of sensor augmented pump (SAP) compared to continuous subcutaneous insulin infu-sion therapy (CSII), in Swedish type 1 diabetic patients (T1D).

    Methods: The Core Diabetes Model is a simulation model to determine the long-term health economic outcomes of diabetes interventions. It was used to project the incidence of diabetes-related complications over a lifetime horizon, based on a) a meta-analysis compar-ing SAP versus CSII for the uncontrolled T1D population and b) on a randomized trial for the hypo-unaware population. The meta-analysis showed that for the cohort based on the Swedish registry NDR 2014, with a mean HbA1c of 63.14 mmol/mol, age of 46 years and a diabetes duration of 24-years led to a reduction of -0.58% versus -0.14% HbA1c, for SAP and CSII respectively. In the hypo-unaware popula-tion severe hypoglycemic events were observed at 2.2 per 100 patient’s months and 0 for CSII and SAP respectively.

    Results: The incremental cost-effectiveness ratio (ICER) was 251’896 SEK per Quality Adjusted Life Year gained (QALY) based on a societal perspective for the uncontrolled population. In the hypo-unaware population the ICER was 139’795 SEK/QALY. The improvement in QALYs were 1.07 and 1.88 years in favor of SAP in the uncontrolled and hypo-unaware population respectively. Additional related costs were partially offset by the savings due to the reduction in complications. Delay of onset of complications were achieved with SAP compared to CSII alone, such as neuropathy (1.04 years), ulcer (0.92 years) and stroke (0.64 years).

    Conclusions: These results indicate that accordingly to commonly accepted threshold in Sweden, SAP with predictive suspend function compared to CSII alone can be considered as good value for money in T1D both indications: uncontrolled and hypo-unaware. Extensive sensitivity analysis on key drivers confirmed the robustness of results.

1 - 7 av 7
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf